EUCTR2013-004567-30-HU进行中（未招募）不适用
A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Newly diagnosed men and women with unilateral subfoveal choroideal neovascularization secondary to age-related macular degeneration
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Additional eye disease that could compromizse best corrected visual acuity, such as uncontrolled glaucoma
研究者
相似试验
进行中（未招募）
1 期
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratioewly diagnosed unilateral wet age-related macular degeneration (wAMD)MedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853EUCTR2013-004567-30-DEBoehringer Ingelheim Pharma GmbH & Co. KG30
进行中（未招募）
不适用
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratioEUCTR2013-004567-30-ATBoehringer Ingelheim RCV GmbH & Co KG70
进行中（未招募）
不适用
A study to compare pediatric patients ages 12-17 to adult patients ages 18-64 and see how much study drug SPRIX is in the blood, how safe the study drug SPRIX is and how well it decreases pain after surgery.EUCTR2013-000938-35-PLuitpold Pharmaceuticals, Inc.59
进行中（未招募）
不适用
An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension iPAHTreatment of pulmonary arterial hypertension in children.MedDRA version: 6.1Level: PTClassification code 10037405EUCTR2004-005157-63-ITACTELION PHARMACEUTICALS ITALIA35
进行中（未招募）
不适用
A Phase 1 study of the body and tumour effects of CUDC-101 in HER2 positive breast cancer patientsEUCTR2012-003064-47-GBCuris, Inc.